Suppr超能文献

男性骨质疏松症——病因、诊断挑战及治疗方法

Male osteoporosis-what are the causes, diagnostic challenges, and management.

作者信息

Björnsdottir Sigridur, Clarke Bart L, Mannstadt Michael, Langdahl Bente L

机构信息

Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden.

Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, USA.

出版信息

Best Pract Res Clin Rheumatol. 2022 Sep;36(3):101766. doi: 10.1016/j.berh.2022.101766. Epub 2022 Aug 9.

Abstract

Osteoporosis is underrecognized and undertreated in men, even though up to 25% of fractures in patients over the age of 50 years occur in men. Men develop osteoporosis with normal aging and accumulation of comorbidities that cause bone loss. Secondary causes of bone loss may be found in up to 60% of men with osteoporosis. Mortality in men who experience major fragility fracture is greater than in women. Diagnosis of osteoporosis in men is similar to women, based on low-trauma or fragility fractures, and/or bone mineral density dual-energy X-ray absorptiometry (DXA) T-scores at or below -2.5. Because most clinical trials with osteoporosis drugs in men were based on bone density endpoints, not fracture reduction, the antifracture efficacy of approved treatments in men is not as well documented as that in women. Men at a high risk of fracture should be offered treatment to reduce future fractures.

摘要

骨质疏松症在男性中未得到充分认识和治疗,尽管50岁以上患者中高达25%的骨折发生在男性身上。男性随着年龄的正常增长以及导致骨质流失的合并症的积累而患上骨质疏松症。高达60%的男性骨质疏松症患者可能存在骨质流失的继发原因。发生严重脆性骨折的男性的死亡率高于女性。男性骨质疏松症的诊断与女性相似,基于低创伤或脆性骨折,和/或骨密度双能X线吸收法(DXA)T值在-2.5及以下。由于大多数针对男性骨质疏松症药物的临床试验基于骨密度终点,而非骨折减少情况,因此获批治疗方法在男性中的抗骨折疗效不如在女性中记录得那么充分。骨折高危男性应接受治疗以减少未来骨折的发生。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验